The EC has granted expanded approval to BMS' Breyanzi, to treat adults with relapsed or refractory follicular lymphoma (FL).

Twice-daily application of ruxolitinib cream demonstrated an ability to reduce itching and blistering in prurigo nodularis, a ...

CTA approval marks Anocca’s transition to a clinical-stage companyFirst-in-human VIDAR-1 trial begins with the deployment of ...

AstraZeneca bought Belgian biotech company EsoBiotec in a deal valued at up to $1 billion, to expand its cell-therapy portfolio.

AstraZeneca will acquire EsoBiotec for a total consideration of up to $1billion, on a cash and debt free basis. This will ...

AstraZeneca will acquire all outstanding equity of EsoBiotec for a total consideration of up to $1,000m, on a cash and debt free basis. This will include an initial payment of $425m on deal closing, ...

The tumult of large-scale cuts to federal spending, pullbacks of civil rights protections, and new tariffs getting announced ...

Dolutegravir plus lamivudine shows comparable efficacy and safety with standard-of-care three-drug regimen in patients with ...

Inter-atrial shunt device therapy has shown mixed results in clinical trials, with clinical 'non-responders' typically showing features of more advanced heart failure. We aimed to analyse the ...

Akeso Inc. (9926.HK) announced that its innovative, self-developed anti-PD-1 monoclonal antibody, penpulimab, has been officially approved by the National Medical Products Administration (NMPA) for ...

Having established success in cancer, biopharma is now looking to leverage CAR T therapies against a new target, autoimmune ...

Ashton had been tormented by fear that he would be rejected by his family in the weeks leading up to his coming out in 2012.